For the quarter ended June 2026, Eli Lilly (LLY Quick QuoteLLY - Free Report) reported revenue of $22.97 billion, up 47.7% over the same period last year. EPS came in at $8.38, compared to $6.31 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $20.26 billion, representing a surprise of +13.38%. The company delivered an EPS surprise of +39.43%, with the consensus EPS estimate being $6.01.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Lilly performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Cyramza (Ramucirumab /IMC-1121B)- US: $112 million versus the two-analyst average estimate of $103.53 million. The reported number represents a year-over-year change of -8.1%.
• Revenue- International- Humulin: $50 million versus the two-analyst average estimate of $50.75 million. The reported number represents a year-over-year change of -5.7%.
• Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- US: $908 million compared to the $543.67 million average estimate based on two analysts. The reported number represents a change of +22.1% year over year.
• Revenue- Trulicity (Dulaglutide / GLP-1 Fc / LY2189265)- ROW: $312 million compared to the $308.19 million average estimate based on two analysts. The reported number represents a change of -10.5% year over year.
• Revenue- Cyramza (Ramucirumab /IMC-1121B)- Total: $256 million compared to the $216.64 million average estimate based on two analysts. The reported number represents a change of +0.9% year over year.
• Revenue- Humulin: $153 million versus the two-analyst average estimate of $157.59 million. The reported number represents a year-over-year change of -12.7%.
• Revenue- Jardiance (Empagliflozin/BI 10773)- Total: $1.23 billion versus the two-analyst average estimate of $698.79 million. The reported number represents a year-over-year change of +78.6%.
• Revenue- Immunology: $1.42 billion compared to the $1.39 billion average estimate based on two analysts. The reported number represents a change of +12.9% year over year.
• Revenue- Olumiant/Baricitinib (LY3009104)/JAK1/JAK2 Inhibitor- Total: $258 million compared to the $254.54 million average estimate based on two analysts.
• Revenue- Taltz (Ixekizumab / LY2439821 / IL-17)- Total: $856 million compared to the $845.57 million average estimate based on two analysts. The reported number represents a change of +1% year over year.
• Revenue- Verzenio- Total: $1.47 billion compared to the $1.56 billion average estimate based on two analysts. The reported number represents a change of -1% year over year.
• Revenue- Emgality (Galcanezumab)- Total: $191 million versus $205.14 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -5% change.

View all Key Company Metrics for Lilly here>>>

Shares of Lilly have returned -9.7% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.